|
Getting your Trinity Audio player ready...
|
Segal Trials, a privately held network of clinical research sites throughout South Florida, has announced that its investigators and the site are the first in the United States to conduct a large, randomized clinical trial to investigate MM-120 (LSD D-tartrate), for the treatment of Generalized Anxiety Disorder (GAD).
Segal Trials’ investigators administered the first dose of MM-120 to a study participant on Aug. 24 at The Center for Psychedelic and Cannabis Research in Miami Lakes.
Dr. Rishi Kakar, medical director and chief scientific officer at Segal Trials, serves as a principal investigator for the MM-120 trial, which is a randomized, double-blind, parallel-group design study to evaluate the potential effectiveness of MM-120 in patients with GAD.
“MindMed’s compound has the potential to change the way clinicians treat GAD,” Dr. Kakar said. “Certainly, conducting the first trial of its kind in the nation puts our companies at the forefront of psychedelic pharmacological research.”
Dr. Kakar and his team will conduct the trial at Segal’s Center for Psychedelic and Cannabis Research, which was specifically built to create a structured inpatient environment that ensures patient safety and comfort.
About Generalized Anxiety Disorder (GAD)
GAD is a chronic, often debilitating mental health disorder that affects approximately 6 percent of U.S. adults in their lifetimes. Symptoms of GAD include excessive anxiety and worry that persists for over six months, which can lead to significant impairments in social, occupational, and other functioning, according to the National Institute of Mental Health (NIMH).
While there is substantial diagnostic overlap between GAD, Major Depressive Disorder (MDD) and other major mental health disorders, there has been very little innovation focused on the treatment of GAD in the past several decades due to the shift in focus from anxiety disorders like GAD toward depressive disorders like MDD, driven by the marketing of serotonin reuptake inhibitors starting in the 1990s.
About Segal Trials
Segal Trials, founded in 1998, is a privately held network of research sites throughout South Florida conducting Phase I-IV research trials that have led to 54 FDA-approved medications and devices. The company’s trials focus on psychiatry, neurology, addiction, insomnia, infectious diseases, vaccine development, and women’s health; and it runs trials in outpatient, inpatient, PSG, and residential care facility settings.
Segal Trials, founded in 1998, is a privately held network of five research sites throughout South Florida conducting Phase I-IV research trials with a primary emphasis on psychiatry, neurology, addiction, insomnia, general medicine, healthy volunteers, infectious diseases, vaccines, and women’s health.
To date, Segal Trials has been an instrumental part in conducting studies resulting in 48 medications and devices that are FDA approved and are changing the quality of life for millions. In addition to conducting clinical trials, Segal Trials also offers data management, bioanalytical lab analysis, medical writing, protocol design and review, project management, budget development and clinical data monitoring services through established vendor relationships and inhouse resources.
Segal Trials is regarded as an innovator and a leader in the advancement of medicine with a strong dedication to the community it serves by spreading awareness about clinical trials as a potential care option. Segal Trials is affiliated with Compass Health Systems, a behavioral healthcare group practice serving the community since 1990.
Segal Trials, additionally, partners with local South Florida Geriatric Residential Care Facilities for inpatient research studies in neurology.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain, and neurology. The company is developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine, and acetylcholine systems. MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
To see more #Miaminews from #Aventura to #Coralgables to #SouthMiami, #Pinecrest, #Palmetto Bay and #Cutler Bay and all throughout #Miamidadecounty go to:
www.communitynewspapers.com
